Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE1A | P54750 | 1/20 | 0.52 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.52 |
| ▸ | PDE4A | P27815 | 8/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 7/20 | 0.43 |
| ▸ | PDE4C | Q08493 | 7/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 7/20 | 0.43 |
| ▸ | FEN1 | P39748 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.38 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2411440 | 0.93 | PDE1A (0.52) | PDE1APDE1BPDE4APDE4BPDE4C | |
| SCHEMBL2408536 | 0.91 | PDE1A (0.55) | PDE1APDE1BPDE4APDE4BPDE4C | |
| SCHEMBL2411594 | 0.90 | PDE1A (0.55) | PDE1APDE1BPDE4APDE4BPDE4C | |
| SCHEMBL2411232 | 0.87 | CYP3A4 (0.53) | PDE1APDE1BPDE4APDE4BPDE4C | |
| SCHEMBL2410839 | 0.87 | PDE1A (0.66) | PDE1APDE1BPDE4APDE4BPDE4C | |
| SCHEMBL2415126 | 0.85 | PDE1A (0.46) | PDE1APDE1BPDE4APDE4BPDE4C | |
| SCHEMBL2410002 | 0.85 | PDE1A (0.46) | PDE1APDE1BPDE4APDE4BPDE4C | |
| SCHEMBL2411012 | 0.84 | AR (0.50) | PDE1APDE1BPDE4APDE4BPDE4C | |
| SCHEMBL4189450 | 0.83 | PDE1A (0.53) | PDE1APDE1BPDE4APDE4BPDE4C | |
| SCHEMBL4197168 | 0.83 | PDE1A (0.50) | PDE1APDE1BPDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1559716-B1 | PYRAZOLONAPHTHYRIDINE DERIVATIVE | ASKA PHARM CO LTD (JP) | 2011-09-14 | — | — | EP | disclosed |
| US-20100093782-A1 | Pyrazolonaphthyridine derivatives | KANAZAWA HASHIME | 2010-04-15 | — | — | US | disclosed |
| US-7608716-B2 | Pyrazolonaphthyridine derivative | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2009-10-27 | — | — | US | disclosed |
| US-20060040972-A1 | Pyrazolonaphthyridine derivative | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2006-02-23 | — | — | US | disclosed |
| EP-1559716-A1 | PYRAZOLONAPHTHYRIDINE DERIVATIVE | Grelan Pharmaceutical Co., Ltd. (JP) | 2005-08-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040972-A1 | Pyrazolonaphthyridine derivative | PDE3B, PDE3A, PDE4A | PDE1A 28/4885PDE1B 24/4885PDE4A 3/4885 |
| US-20100093782-A1 | Pyrazolonaphthyridine derivatives | PDE3B, PDE3A, PDE4A | PDE1A 30/4885PDE1B 23/4885PDE4A 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.